November 4, 2010Anesthesia & Analgesia
Dopexamine Has No Additional Benefit in High-Risk Patients Receiving Goal-Directed Fluid Therapy Undergoing Major Abdominal Surgery
Why the study?
Does dopexamine reduce postoperative morbidity in high-risk patients receiving goal-directed fluid therapy undergoing major abdominal surgery?
Population
124 patients undergoing elective major colorectal or urological surgery who had an anaerobic threshold of…
Comparison
Dopexamine for 24 hours, added to goal-directed… vs Saline 0.9% for 24 hours, added to goal-directed…
Design
RCT
Follow-up
5 days
Authors
Discussion
Loading...
Member takes
Implication
Dopexamine adds no morbidity benefit to goal-directed fluid therapy; confirms limited role in high-risk abdominal surgery.
Structured PICO
Does dopexamine reduce postoperative morbidity in high-risk patients receiving goal-directed fluid therapy undergoing major abdominal surgery?
P
Population
124 patients undergoing elective major colorectal or urological surgery who had an anaerobic threshold (AT) of <11 mL/kg/min or an AT of 11 to 14 mL/kg/min with a history of ischemic heart disease
I
Intervention
Dopexamine (0.5 μg/kg/min) for 24 hours, added to goal-directed fluid therapy
C
Comparator
Saline 0.9% for 24 hours, added to goal-directed fluid therapy
O
Outcome
Postoperative morbidity measured by the Postoperative Morbidity Surveycomposite
Routine use of low-dose dopexamine does not confer additional clinical benefit in reducing postoperative morbidity in high-risk patients receiving goal-directed fluid therapy during major abdominal surgery.
Cite This Study
Davies et al. (2010) studied this question.